QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)

Corcept Therapeutics Stock Price, News & Analysis (NASDAQ:CORT)

$25.45
+0.18 (+0.71%)
(As of 11/28/2023 ET)
Compare
Today's Range
$24.88
$25.48
50-Day Range
$24.82
$32.99
52-Week Range
$17.86
$34.28
Volume
406,538 shs
Average Volume
726,653 shs
Market Capitalization
$2.62 billion
P/E Ratio
31.42
Dividend Yield
N/A
Price Target
$32.19

Corcept Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
26.5% Upside
$32.19 Price Target
Short Interest
Bearish
17.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.59
Upright™ Environmental Score
News Sentiment
1.87mentions of Corcept Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$2.29 M Sold Last Quarter
Proj. Earnings Growth
-10.99%
From $0.91 to $0.81 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.34 out of 5 stars

Medical Sector

268th out of 949 stocks

Pharmaceutical Preparations Industry

113th out of 434 stocks


CORT stock logo

About Corcept Therapeutics Stock (NASDAQ:CORT)

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

CORT Stock Price History

CORT Stock News Headlines

Corcept Therapeutics Inc CORT
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Where Corcept Therapeutics Stands With Analysts
Secure your stake in the Smart Home industry.
Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.
5 Analysts Have This to Say About Corcept Therapeutics
Corcept Therapeutics plunges amid patent trial with Teva
See More Headlines
Receive CORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
11/28/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/27/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:CORT
CUSIP
21835210
Employees
299
Year Founded
1998

Price Target and Rating

Average Stock Price Target
$32.19
High Stock Price Target
$47.50
Low Stock Price Target
$22.00
Potential Upside/Downside
+28.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$101.42 million
Pretax Margin
24.89%

Debt

Sales & Book Value

Annual Sales
$401.86 million
Cash Flow
$0.96 per share
Book Value
$4.66 per share

Miscellaneous

Free Float
83,908,000
Market Cap
$2.59 billion
Optionable
Optionable
Beta
0.43

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report














CORT Stock Analysis - Frequently Asked Questions

Should I buy or sell Corcept Therapeutics stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CORT shares.
View CORT analyst ratings
or view top-rated stocks.

What is Corcept Therapeutics' stock price target for 2024?

7 analysts have issued twelve-month price targets for Corcept Therapeutics' stock. Their CORT share price targets range from $22.00 to $47.50. On average, they expect the company's stock price to reach $32.19 in the next year. This suggests a possible upside of 26.5% from the stock's current price.
View analysts price targets for CORT
or view top-rated stocks among Wall Street analysts.

How have CORT shares performed in 2023?

Corcept Therapeutics' stock was trading at $20.31 on January 1st, 2023. Since then, CORT shares have increased by 25.3% and is now trading at $25.45.
View the best growth stocks for 2023 here
.

Are investors shorting Corcept Therapeutics?

Corcept Therapeutics saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 15,270,000 shares, an increase of 8.1% from the October 31st total of 14,120,000 shares. Based on an average daily volume of 739,700 shares, the short-interest ratio is presently 20.6 days. Approximately 17.4% of the shares of the stock are short sold.
View Corcept Therapeutics' Short Interest
.

When is Corcept Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our CORT earnings forecast
.

How were Corcept Therapeutics' earnings last quarter?

Corcept Therapeutics Incorporated (NASDAQ:CORT) posted its quarterly earnings results on Wednesday, November, 1st. The biotechnology company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.22 by $0.06. The biotechnology company had revenue of $123.60 million for the quarter, compared to the consensus estimate of $119.71 million. Corcept Therapeutics had a net margin of 20.20% and a trailing twelve-month return on equity of 18.99%. The firm's quarterly revenue was up 21.5% compared to the same quarter last year. During the same period last year, the business earned $0.30 earnings per share.

What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO?

6 employees have rated Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among the company's employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Corcept Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), CA (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI).

Who are Corcept Therapeutics' major shareholders?

Corcept Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Ingalls & Snyder LLC (8.13%), Boston Trust Walden Corp (1.78%), Federated Hermes Inc. (1.64%), Northern Trust Corp (1.24%), Morgan Stanley (1.19%) and Invesco Ltd. (0.92%). Insiders that own company stock include Daniel N Swisher Jr, Daniel N Swisher, Jr, David L Mahoney, G Leonard Baker Jr, G Leonard Baker, Jr, Gary Charles Robb, Hazel Hunt, Joseph Douglas Lyon, Joseph K Belanoff and Sean Maduck.
View institutional ownership trends
.

How do I buy shares of Corcept Therapeutics?

Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CORT) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -